Literature DB >> 33748897

Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival.

Philip M Spanheimer1, Ian Ganly1, Joanne F Chou2, Marinela Capanu2, Aradhya Nigam1, Ronald A Ghossein3, R Michael Tuttle4, Richard J Wong1, Ashok R Shaha1, Murray F Brennan1, Brian R Untch5.   

Abstract

BACKGROUND: Patients with medullary thyroid carcinoma (MTC) often receive lateral lymph node dissection with total thyroidectomy when calcitonin levels are elevated, even in the absence of structural disease, but the effect of this intervention on disease-specific outcomes is not known. PATIENTS AND METHODS: We retrospectively reviewed patients from 1986 to 2017 who underwent thyroidectomy with curative intent for MTC at our institution. The association of disease-specific survival and clinicopathologic features was examined using univariate and multivariate Cox regression.
RESULTS: We identified 316 patients who underwent curative resection for MTC. Overall and disease-specific survival were 76% and 86%, respectively, at 10 years. To investigate the effect of prophylactic ipsilateral lateral lymph node dissection, we analyzed 89 patients without known structural disease in the neck lymph nodes at the time of resection and preoperative calcitonin > 200 pg/ml, of whom 45 had an ipsilateral lateral lymph node dissection (LND) and 44 did not. There were no differences in tumor size or preoperative calcitonin levels. There was no difference at 10 years in cumulative incidence of recurrence in the neck (20.9% LND vs. 30.4% no LND, p = 0.46), cumulative incidence of distant recurrence (18.3% vs. 18.4%, p = 0.97), disease-specific survival (86% vs. 93%, p = 0.53), or overall survival (82% vs. 90%, p = 0.6).
CONCLUSION: Lateral neck dissection in the absence of clinical or radiologic abnormal lymph nodes is not associated with improved survival in patients with MTC.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2021        PMID: 33748897      PMCID: PMC8452790          DOI: 10.1245/s10434-021-09683-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


  1 in total

1.  Localization and resection of clinically inapparent medullary carcinoma of the thyroid.

Authors:  J A Norton; J L Doppman; M F Brennan
Journal:  Surgery       Date:  1980-06       Impact factor: 3.982

  1 in total
  5 in total

1. 

Authors:  凡 吴; 天晗 周; 凯宁 陆; 婷 潘; 烨钦 倪; 玲倩 赵; 可成 姜; 煜 张; 定存 罗
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

2.  Risk factors for lateral cervical lymph node metastasis in medullary thyroid carcinoma.

Authors:  Fan Wu; Tianhan Zhou; Kaining Lu; Ting Pan; Yeqin Ni; Lingqian Zhao; Kecheng Jiang; Yu Zhang; Dingcun Luo
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

3.  The Prediction of Metastases of Lateral Cervical Lymph Node in Medullary Thyroid Carcinoma.

Authors:  Tian-Han Zhou; Ling-Qian Zhao; Yu Zhang; Fan Wu; Kai-Ning Lu; Lin-Lin Mao; Ke-Cheng Jiang; Ding-Cun Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-17       Impact factor: 5.555

Review 4.  Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?

Authors:  Krzysztof Kaliszewski; Maksymilian Ludwig; Bartłomiej Ludwig; Agnieszka Mikuła; Maria Greniuk; Jerzy Rudnicki
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

Review 5.  Management of lymph nodes in medullary thyroid carcinoma: A review.

Authors:  Ali Shaghaghi; Abolfazl Salari; Amirmohsen Jalaeefar; Mohammad Shirkhoda
Journal:  Ann Med Surg (Lond)       Date:  2022-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.